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Gemcitabine plus cisplatin (GEM/cis) displays similar 
efﬁcacy to methotrexate, vinblastine, doxorubicin plus
cisplatin (MVAC) in the treatment of advanced bladder
cancer. The main advantage of GEM/cis over MVAC is
superior tolerability, as evidenced by a lower incidence of
severe adverse effects.
OBJECTIVE: To determine whether GEM/cis offers value
for money compared with MVAC. 
METHODS: Direct medical costs were calculated for
each treatment, based on resource utilisation data 
collected during a randomised phase III trial. Utility
values were determined to capture the quality of life
(QoL) differences between the two therapies. A novel
methodology, involving the use of discrete-choice con-
joint analysis, was employed to examine the value asso-
ciated with the toxicity proﬁle of GEM/cis compared with
MVAC. Attributes included in the analysis (alopecia,
weight improvement, mouth ulcers, thrombocytopenia,
febrile neutropenia and length of life) were obtained from
a survey of oncology nurses. Length of life was included
to allow the trade-off between length of life and side
effects to be determined. This approach enables discrete
utility values to be calculated for each attribute.
RESULTS: Survey responses indicated a preference for
GEM/cis treatment. The extra utility beneﬁt with
GEM/cis was 0.204, mostly derived from reduced risk 
of febrile neutropenia, mouth ulcers and alopecia. The
incremental cost per quality-adjusted life-year gained was
AUS$25,000 (US$50,000). This is within an acceptable
range for Australia. Sensitivity analyses indicated the
results were robust. Using these results, a cost-utility
analysis was conducted and submitted to the Australian
Pharmaceutical Beneﬁts Advisory Committee to assist in
deciding whether GEM/cis should receive public subsidy.
GEM/cis gained funding for the treatment of bladder
cancer.
CONCLUSIONS: GEM/cis offers comparable survival
with a superior toxicity proﬁle and QoL beneﬁt. The
study demonstrated that utility values can be derived
using a discrete-choice conjoint analysis approach.
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OBJECTIVES: Framingham-risk equations to estimate
coronary heart disease risk (CHD-risk) are used through-
out Europe, assuming their validity and generalizability.
The objective of our analysis is to check its accuracy using
prevalence and mortality data for Germany and other
sources of information. 
METHODS: We constructed a Markov model following
an average cohort of 30 years old persons without CHD,
to investigate future prevalences and the percentage of
persons dying from CHD. With respect to these outcomes
average CHD incidence rates interact with quantities such
as general mortality rates, CHD-fatality rates and 
long-term prognosis of CHD cases. In the baseline model
average age- and gender-speciﬁc CHD incidence rates
were based on the current risk factor distribution 
in Germany (German Health Survey 1998) and the 
Framingham risk-equations of Anderson (1991). In the
alternative model incidence rates were calculated so that
future probabilities of dying from CHD match current
data from the Statistical Yearbook.
RESULTS: Transferring the Framingham risk equations
to Germany vastly overestimates other ﬁgures on 
prevalence and CHD-Mortality below the age of 60 years.
Average CHD-risks increase with age but at a lower rate
as compared to total mortality rates. In comparison to the
baseline model calculated incidence rates in the alterna-
tive model are generally more than 50% lower than in
the baseline model under the age of 60 for both males
and females and 46% lower for males and 25% lower for
females at the age of 70.
CONCLUSIONS: At least in Europe Framingham 
risk-equations have to be used with caution nowadays.
Apart from continental differences, Framingham risk-
equations do not yet reﬂect recent time trends in CHD-
risk, which cannot be attributed to changes in risk factors.
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OBJECTIVES: To evaluate the variability of case-mix
adjusted, estimated costs for pharmaceutical services
across acute care hospitals in the U.S., and to develop a
metric to be used in differentiating hospitals with regard
to case-mix adjusted intensity of pharmaceutical services. 
METHODS: Solucient all-payer, inpatient data from
acute care hospitals were used to derive cost estimates for
inpatient pharmaceutical services. These data have been
extensively published. The Medicare Cost Reports were
